Cytotoxicity against human doxorubicin-resistant K562/Adr cells in presence of 1 uM doxorubicin after 48 hrs by MTT assay
CC(=C)C1CCC2(C1C3CCC4C5(CCC(=O)C(C5CCC4(C3(CC2)C)C)(C)C)C)C(=O)O,48400
CC(=C)C1CCC2(C(C1(C)CCC(=O)O)CCC3=C4CC(CCC4(CCC32C)C)(C)C)C,24800
CC1C2C3CCC4C(C3(CCC2(CCC1=C)C)C)(CCC(C4(C)CCC(=O)O)C(=C)C)C,100000
CC1(C2CCC3(C(C2(CCC1OC(=O)CC(=O)O)C)CCC4C3(CCC4C5(CCC(O5)C(C)(C)O)C)C)C)C,42500
CC1(C2CCC3(C(C2(CCC1OC(=O)CC(=O)OC)C)CCC4C3(CCC4C5(CCC(O5)C(C)(C)O)C)C)C)C,41100
CC(=O)OC1CC2C3(CCC(C(C3CCC2(C4(C1C(CC4)C5(CCC(O5)C(C)(C)O)C)C)C)(C)C)OC(=O)CC(=O)O)C,34500
CC1(C2CCC3(C(C2(CCC1O)C)CCC4C3(CCC4C5(CCC(O5)C(C)(C)O)C)C)C)C,45200
CC(=O)OC1CCC2(C3CCC4C(CCC4(C3(CCC2C1(C)C)C)C)C5(CCC(O5)C(C)(C)O)C)C,68300
CC1(C2CCC3(C(C2(CCC1=O)C)CCC4C3(CCC4C5(CCC(O5)C(C)(C)O)C)C)C)C,100000
CC(=O)OC1CC2C3(CCC(C(C3CCC2(C4(C1C(CC4)C5(CCC(O5)C(C)(C)O)C)C)C)(C)C)O)C,15300
CC1(C2CCC3(C(C2(CCC1=O)C)CCC4C3(CCC5C4(CCC5C(C)(C)O)C)C)C)C,100000
CC(=C)C1CCC2(C(C1(C)CCC(=O)OC)CCC3C2(CCC3C4(CCC(O4)C(C)(C)O)C)C)C,47100
CC1(C2CCC3(C(C2(CCC1=O)C)CCC4C3(CCC4C5(CCC(=O)O5)C)C)C)C,100000
CC1(C2CCC3(C(C2(CCC1O)C)CCC4C3(CCC4C5(CCC(=O)O5)C)C)C)C,100000
CC(=C)C(CCC(C)(C1CCC2(C1CCC3C2(CCC4C3(CCC(=O)C4(C)C)C)C)C)O)O,50400
CC(=CCCC(C)(C1CCC2(C1CCC3C2(CCC4C3(CCC(=O)C4(C)C)C)C)C)O)C,100000
CC(=O)OC1CC2C3(CCC(C(C3CCC2(C4(C1C(CC4)C5(CCC(O5)C(C)(C)O)C)C)C)(C)C)OC(=O)CC(=O)OC)C,10600
CC(=O)OC1CCC2(C(C1(C)C)CCC3(C2CC(C4C3(CCC4C5(CCC(O5)C(C)(C)O)C)C)OC(=O)C)C)C,23900
CC1(C2CCC3(C(C2(CCC1=O)C)CCC4C3(CCC4C5(CCC(O5)C(C)(C)O)C)C)C)C,100000
CC1(C2CCC3(C(C2(CCC1OC(=O)CC(=O)OC)C)CCC4C3(CCC4C5(CCC(=O)O5)C)C)C)C,26500
